Network and cell study links carboplatin to four melanoma targets
Network analysis and B16F0 cell experiments linked carboplatin with CDKN1A, BRCA1, PTEN and AKT1 in melanoma, without establishing clinical benefit.
Network analysis and B16F0 cell experiments linked carboplatin with CDKN1A, BRCA1, PTEN and AKT1 in melanoma, without establishing clinical benefit.
A study of 1,009 Chinese breast cancer patients found that BRCA1 mutation carriers had far higher rates of complete tumor ...
A new survey of nearly 1,000 women with hereditary breast cancer susceptibility genes reveals that financial and emotional support services ...
A widely used lactation-suppressing drug, cabergoline, was linked to a sharply lower postpartum breast cancer risk in women and halved ...
A randomized trial at MD Anderson Cancer Center found that personalized navigation support raised BRCA genetic testing uptake among at-risk ...
A new computational pipeline called HiFIseek systematically links damaging non-coding mutations to cancer genes, revealing that regulatory regions of drivers ...
A Mayo Clinic-led proteomic study of nearly 5,000 proteins in nonmalignant breast tissue reveals that cancer-free BRCA1/2 mutation carriers show ...
A case report in Oncoscience describes high-grade serous ovarian carcinoma diagnosed at ten weeks of gestation, illustrating the diagnostic and ...
New research shows carboplatin drives the expansion of TP53-mutant blood clones far more strongly than PARP inhibitors, while inherited homologous ...
A retrospective cohort of 259 Colombian breast cancer patients with germline pathogenic variants found a ten-year overall survival of 75 ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine